First Time Loading...

Marinus Pharmaceuticals Inc
NASDAQ:MRNS

Watchlist Manager
Marinus Pharmaceuticals Inc Logo
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Watchlist
Price: 1.48 USD -1.99% Market Closed
Updated: May 7, 2024
Section:
 

Wall Street
Price Targets

MRNS Price Targets Summary
Marinus Pharmaceuticals Inc

Wall Street analysts forecast MRNS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNS is 8.98 USD with a low forecast of 2.02 USD and a high forecast of 28.35 USD.

MRNS Lowest Forecast
Wall Street Target
2.02 USD
36% Upside
MRNS Average Forecast
Wall Street Target
8.98 USD
506% Upside
MRNS Highest Forecast
Wall Street Target
28.35 USD
1 816% Upside
Lowest
Price Target
2.02 USD
36% Upside
Average
Price Target
8.98 USD
506% Upside
Highest
Price Target
28.35 USD
1 816% Upside

MRNS Last Price Targets
Marinus Pharmaceuticals Inc

The latest public price target was made on Apr 16, 2024 by Brian Skorney from Robert W. Baird , who expects MRNS stock to rise by 35% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Brian Skorney
Robert W. Baird
2 USD
Upside 35%
3 weeks ago
Apr 16, 2024
Baird Downgrades Marinus Pharmaceuticals (MRNS) to Neutral, 'Phase 3 RAISE Study Doesn't Hit at Interim'
StreetInsider
Sector Perform
RBC Capital
3 USD
Upside 103%
3 weeks ago
Apr 15, 2024
Marinus Pharmaceuticals downgraded to Sector Perform at RBC Capital
TheFly
Jay Olson
Oppenheimer
9 USD
Upside 508%
1 month ago
Mar 28, 2024
Oppenheimer Reiterates Perform Rating on Marinus Pharmaceuticals (MRNS)
StreetInsider
Brian Skorney
Robert W. Baird
Price Target 2 USD
Upside/Downside 35%
View Source
Sector Perform
RBC Capital
Price Target 3 USD
Upside/Downside 103%
View Source
Jay Olson
Oppenheimer
Price Target 9 USD
Upside/Downside 508%
View Source
Marinus Pharmaceuticals Inc Competitors:
Price Targets
GS71
GSK plc
12% Upside
002437
Harbin Gloria Pharmaceuticals Co Ltd
361% Upside
SCTL
Societal CDMO Inc
2% Upside
603590
Beijing Konruns Pharmaceutical Co Ltd
43% Upside
GS71
GSK plc
12% Upside
002437
Harbin Gloria Pharmaceuticals Co Ltd
361% Upside
SCTL
Societal CDMO Inc
2% Upside
603590
Beijing Konruns Pharmaceutical Co Ltd
43% Upside
HCM
HUTCHMED (China) Ltd
21% Upside
000623
Jilin Aodong Pharmaceutical Group Co Ltd
150% Upside
LLY
Eli Lilly and Co
10% Upside
LABB
Genomma Lab Internacional SAB de CV
2% Downside

Revenue
Forecast

Revenue Estimate
Marinus Pharmaceuticals Inc

The compound annual growth rate of Marinus Pharmaceuticals Inc's revenue for the next 3 years is 73%.

N/A
Past Growth
73%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Marinus Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Marinus Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-74%
Average Miss
What are analyst estimates?

See Also

Summary
MRNS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRNS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRNS stock valuation using valuation multiples.
Wall Street Estimates
MRNS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRNS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MRNS's stock price target?
Price Target
8.98 USD

According to Wall Street analysts, the average 1-year price target for MRNS is 8.98 USD with a low forecast of 2.02 USD and a high forecast of 28.35 USD.

What is Marinus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
73%

The compound annual growth rate of Marinus Pharmaceuticals Inc's revenue for the next 3 years is 73%.

ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.